|This Slide: #16 of 100|
Slide #16. TetraLogic Pharmaceuticals Corporation — Shape Pharmaceuticals, Inc.
TetraLogic Pharmaceuticals Corporation (TLOG)
Shape Pharmaceuticals, Inc.
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) announced today that it has executed a definitive agreement to acquire by merger 100% of Shape Pharmaceuticals, a privately-held biotechnology company developing suberohydroxamic acid phenyl ester (SHAPE), a novel, tissue-targeted HDAC inhibitor in a topical gel formulation to treat stage IA-IIA Cutaneous T-Cell Lymphoma (CTCL), adding a second clinical-stage oncology compound to the TetraLogic portfolio.
TetraLogic Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. Co. has two clinical-stage product candidates in development: birinapant and suberohydroxamic acid 4-methoxycarbonyl phenyl ester (SHAPE). SHAPE is Co.'s proprietary histone deacetylase inhibitor that it is developing for topical use for the treatment of early-stage cutaneous T-cell lymphoma. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases, which causes apoptosis, or cell-death, in damaged cells.
Open the TLOG Page at The Online Investor »
Free TLOG Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts
Strong Buy (4.00 out of 4)
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite